MyMD Pharmaceuticals (MyMD Pharmaceuticals) Operating Cash Flow per Share : $-6.88 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MyMD Pharmaceuticals Operating Cash Flow per Share?

MyMD Pharmaceuticals's operating cash flow per share for the three months ended in Mar. 2024 was $-0.89. MyMD Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.88.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -30.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for MyMD Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

MYMD' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -30.7 Med: -30.7 Max: -30.7
Current: -30.7

During the past 4 years, MyMD Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was -30.70% per year. The lowest was -30.70% per year. And the median was -30.70% per year.

MYMD's 3-Year OCF Growth Rate is ranked worse than
81.13% of 1235 companies
in the Biotechnology industry
Industry Median: 3.3 vs MYMD: -30.70

MyMD Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for MyMD Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MyMD Pharmaceuticals Operating Cash Flow per Share Chart

MyMD Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-3.77

-16.72

-9.48

-8.42

MyMD Pharmaceuticals Quarterly Data
	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial											-2.85	-2.91	-2.11	-0.97	-0.89

Competitive Comparison of MyMD Pharmaceuticals's Operating Cash Flow per Share

For the Biotechnology subindustry, MyMD Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MyMD Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MyMD Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where MyMD Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

MyMD Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

MyMD Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-12.981	/	1.542
	=	-8.42

MyMD Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-1.912	/	2.141
	=	-0.89

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.88

MyMD Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of MyMD Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

MyMD Pharmaceuticals (MyMD Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyMD Pharmaceuticals Inc (NAS:MYMD) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

DQS:Germany DQS:Germany

Address

855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://www.mymd.com

MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and a monoamine oxidase enzyme type B.

Executives

Paul Rivard	officer: EVP of Operations, GC	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Caroline C Williams	10 percent owner	324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Adam Kaplin	officer: Chief Scientific Officer	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Jude Uzonwanne	director	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Craig Eagle	director	POST OFFICE BOX 4590, NEW YORK NY 10163
Chapman Christopher C Jr	director, officer: President, Chief Med. Officer	C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Ian Rhodes	officer: Interim CFO	1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824
Stuart M Benson	officer: Chief Financial Officer	EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp	10 percent owner	28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber	10 percent owner	C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Robert C Schroeder	director	37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Howard Yeaton	officer: CEO, CFO	79 LLOYD ROAD, HOHOKUS NJ 07423
Tarbox Richard C Iii	director	AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Christopher C Schreiber	director	AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086